VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Safety, efficacy and tolerability of ide-cel in the real-world

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, comments on the results of a study investigating the real-world safety, efficacy, and tolerability of idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory (R/R) multiple myeloma. Overall, it was found that ide-cel was very effective in the real world, and toxicity rates were comparable to what was observed in the KarMMa trial (NCT03361748). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter